Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation

被引:12
|
作者
Webster-Clark, Michael [1 ]
Lund, Jennifer L. [1 ]
Sturmer, Til [1 ]
Poole, Charles [1 ]
Simpson, Ross J. [2 ]
Edwards, Jessie K. [1 ]
机构
[1] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
基金
美国国家卫生研究院;
关键词
Anticoagulation; Generalizability; Medicare; Older adults; Transportability; CLINICAL-TRIALS; ORAL ANTICOAGULANTS; STROKE PREVENTION; ADVERSE EVENTS; WARFARIN; DABIGATRAN; RIVAROXABAN; APIXABAN; OUTCOMES; THERAPY;
D O I
10.1097/EDE.0000000000001230
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Results from trials and nonexperimental studies are often directly compared, with little attention paid to differences between study populations. When target and trial population data are available, accounting for these differences through transporting trial results to target populations of interest provides useful perspective. We aimed to compare two-year risk differences (RDs) for ischemic stroke, mortality, and gastrointestinal bleeding in older adults with atrial fibrillation initiating dabigatran and warfarin when using trial transport methods versus nonexperimental methods. Methods: We identified Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample. To transport treatment effects observed in the randomized evaluation of long-term anticoagulation trial, we applied inverse odds weights to standardize estimates to two Medicare target populations of interest, initiators of: (1) dabigatran and (2) warfarin. Separately, we conducted a nonexperimental study in the Medicare populations using standardized morbidity ratio weighting to control measured confounding. Results: Comparing dabigatran to warfarin, estimated two-year RDs for ischemic stroke were similar with trial transport and nonexperimental methods. However, two-year mortality RDs were closer to the null when using trial transport versus nonexperimental methods for the dabigatran target population (transported RD: -0.57%; nonexperimental RD: -1.9%). Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). Conclusions: Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract:.
引用
收藏
页码:605 / 613
页数:9
相关论文
共 50 条
  • [1] Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran The RE-LY Trial
    Hart, Robert G.
    Diener, Hans-Christoph
    Yang, Sean
    Connolly, Stuart J.
    Wallentin, Lars
    Reilly, Paul A.
    Ezekowitz, Michael D.
    Yusuf, Salim
    STROKE, 2012, 43 (06) : 1511 - +
  • [2] Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial
    Khoo, Chee W.
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (04) : 685 - 687
  • [3] Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial
    Paikin, Jeremy S.
    Haroun, Michelle J.
    Eikelboom, John W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (03) : 279 - 286
  • [4] Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis
    Pablo A. Mendoza
    William F. McIntyre
    Emilie P. Belley-Côté
    Jia Wang
    Ratika Parkash
    Clare L. Atzema
    Alexander P. Benz
    Jonas Oldgren
    Richard P. Whitlock
    Jeff S. Healey
    Journal of Thrombosis and Thrombolysis, 2022, 53 : 74 - 82
  • [5] Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis
    Mendoza, Pablo A.
    McIntyre, William F.
    Belley-Cote, Emilie P.
    Wang, Jia
    Parkash, Ratika
    Atzema, Clare L.
    Benz, Alexander P.
    Oldgren, Jonas
    Whitlock, Richard P.
    Healey, Jeff S.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2022, 53 (01) : 74 - 82
  • [6] Comparison of Dabigatran versus Warfarin in Diabetic Patients with Atrial Fibrillation: Results from the RE-LY Trial
    Darius, Harald
    Clemens, Andreas
    Healey, Jeff S.
    Avezum, Alvaro
    Nagarakanti, Rangadham
    Chin, Ashley
    Noack, Herbert
    Connolly, Stuart
    CIRCULATION, 2012, 126 (21)
  • [7] Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial
    Coppens, Michiel
    Eikelboom, John
    Ezekowitz, Michael
    Clemens, Andreas
    Healy, Jeff
    Wallentin, Lars
    Noack, Herbert
    Yusuf, Salim
    Connolly, Stuart
    CIRCULATION, 2012, 126 (21)
  • [8] Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial
    Ezekowitz, M. D.
    Connolly, S. J.
    Fraessdorf, M.
    Brueckmann, M.
    Kreuzer, J.
    Oldgren, J.
    Reilly, P.
    Yusuf, S.
    Wallentin, L.
    EUROPEAN HEART JOURNAL, 2015, 36 : 862 - 862
  • [9] Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial
    Brambatti, Michela
    Darius, Harald
    Oldgren, Jonas
    Clemens, Andreas
    Noack, Herbert H.
    Brueckmann, Martina
    Yusuf, Salim
    Wallentin, Lars
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Healey, Jeff S.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 196 : 127 - 131
  • [10] Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial
    Nagarakanti, Rangadham
    Connolly, Stuart
    Brueckmann, Martina
    Hart, Robert G.
    Reilly, Paul
    Noack, Herbert
    Clemens, Andreas
    Wallentin, Lars
    Yusuf, Salim
    Ezekowitz, Michael D.
    CIRCULATION, 2013, 128 (22)